设为首页 |加入收藏 |联系我们 |ENGLISH

 

首页

 

期刊概况

 

编委会

 

过刊浏览

 

特邀审稿

 

投稿指南

 

出版发行

 

联系我们

1403~1408.非小细胞肺癌患者血清miR-22 和miR-126 的检测及其临床意义[J].张玉洁,王微微,商安全,魏军.中国肿瘤生物治疗杂志,2017,24(12)
非小细胞肺癌患者血清miR-22 和miR-126 的检测及其临床意义    点此下载全文    点此浏览HTML全文
张玉洁  王微微  商安全  魏军
1.宁夏医科大学临床医学院,宁夏银川750000;2. 盐城市第一人民医院病理科,江苏盐城224001; 3. 同济大学医学院附属同济医院检验科,上海200065;4. 盐城市第六人民医院检验医学科,江苏盐城224005,1.宁夏医科大学临床医学院,宁夏银川750000;2. 盐城市第一人民医院病理科,江苏盐城224001; 3. 同济大学医学院附属同济医院检验科,上海200065;4. 盐城市第六人民医院检验医学科,江苏盐城224005,1.宁夏医科大学临床医学院,宁夏银川750000;2. 盐城市第一人民医院病理科,江苏盐城224001; 3. 同济大学医学院附属同济医院检验科,上海200065;4. 盐城市第六人民医院检验医学科,江苏盐城224005,1.宁夏医科大学临床医学院,宁夏银川750000;2. 盐城市第一人民医院病理科,江苏盐城224001; 3. 同济大学医学院附属同济医院检验科,上海200065;4. 盐城市第六人民医院检验医学科,江苏盐城224005
基金项目:国家自然科学基金资助项目(No. 81460247);宁夏医科大学临床医学一流学科建设项目(No. YXW2017014);2017 年宁夏“研究生教育创新计划”学位点建设项目(No.YXW2017014);宁夏医科大学2015 研究生教育创新计划(No. NXYC201511);盐城市医学科技发展计划项目(No. YK2016074)
DOI:10.3872/j.issn.1007-385X.2017.12.011
摘要:
      目的:探讨液体活检外周血清miR-22 和miR-126 的表达在非小细胞肺癌(NSCLC)发生和转移中的作用。方法:收集盐城市第六人民医院2013 年5 月至2015 年5 月期间确诊的127 例NSCLC患者,设健康对照112 例,采用qPCR检测患者血清中miR-22 和miR-126 的相对表达水平,Logistic回归分析法及ROC曲线分析miR-22 和miR-126 在NSCLC发展与转移预测中的敏感性及特异性。结果:病例组血清miR-22 水平显著高于对照组,而血清miR-126 水平低于对照组(均P<0.05);与腺癌患者相比,鳞状细胞癌患者的血清miR-22 水平显著升高(P<0.05)、血清miR-126 显著降低(P<0.01);与Ⅰ+Ⅱ期患者相比,Ⅲ+Ⅳ期患者血清miR-22 水平升高、miR-126 水平相对降低(均P<0.01);与未转移患者相比,转移患者血清miR-22 水平升高,而血清miR-126 水平降低(均P<0.01);有家族遗传史的患者与没有家族遗传史的患者相比,血清miR-22 水平升高但miR-126 水平降低(均P<0.01)。血清miR-22 与miR-126 水平对NSCLC预测的特异性与敏感性分别为99.11%和84.30%、82.68%和96.40%。血清miR-22 与miR-126 水平对NSCLC转移的特异性与敏感性分别为59.74%和96.00%、84.00%和62.30%。结论:在NSCLC患者血清中,miR-22 呈高表达而miR-26 呈低表达,液体活检miR-22 和miR-126 可作为预测NSCLC的发生及转移的一个生物学指标。
关键词:非小细胞肺癌  microRNA-22;microRNA -126;血清;液体活检
miR-22 and miR-126 expression in serum of patients with non-small cell lung cancer and its clinical significance    Download Fulltext
ZHANG Yujie  WANG Weiwei  SHANG Anquan  WEI Jun
1.Clinical Medicine School, Ningxia Medical University, Yinchuan 750000, Ningxia, China; 2. Departments of Pathology, the First People’s Hospital of Yancheng City, Yancheng 224001, Jiangsu, China; 3. Department of Laboratory Medicine, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China; 4.Departments of Laboratory Medicine, the Sixth People’s Hospital of Yancheng City, Yancheng 224005, Jiangsu, China,1.Clinical Medicine School, Ningxia Medical University, Yinchuan 750000, Ningxia, China; 2. Departments of Pathology, the First People’s Hospital of Yancheng City, Yancheng 224001, Jiangsu, China; 3. Department of Laboratory Medicine, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China; 4.Departments of Laboratory Medicine, the Sixth People’s Hospital of Yancheng City, Yancheng 224005, Jiangsu, China,1.Clinical Medicine School, Ningxia Medical University, Yinchuan 750000, Ningxia, China; 2. Departments of Pathology, the First People’s Hospital of Yancheng City, Yancheng 224001, Jiangsu, China; 3. Department of Laboratory Medicine, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China; 4.Departments of Laboratory Medicine, the Sixth People’s Hospital of Yancheng City, Yancheng 224005, Jiangsu, China and 1.Clinical Medicine School, Ningxia Medical University, Yinchuan 750000, Ningxia, China; 2. Departments of Pathology, the First People’s Hospital of Yancheng City, Yancheng 224001, Jiangsu, China; 3. Department of Laboratory Medicine, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, China; 4.Departments of Laboratory Medicine, the Sixth People’s Hospital of Yancheng City, Yancheng 224005, Jiangsu, China
Fund Project:Project supported by the National Natrural Science Foundation of China(No. 81460247), the First-class Discipline Construction of Clinical Medicine of Ningxia Medical University(No. YXW2017014), the Plan of Postgraduate Education Innovation, Discipline Construction Project of Ningxia (2017) (No. YXW2017014), the 2015 Postgraduate Education Innovation Program of Ningxia Medical University(No. NXYC201511),and the 2016 Medical Science and Technology Development Program of Yancheng City(No. 81460247)
Abstract:
      Objective: To investigate the expression of microRNA-22 (miR-22) and miR-126 in blood serum of patients with non-small cell lung cancer (NSCLC) and explore their role in the occurrence and metastasis of NSCLC.Methods: A total of 127 NSCLC patients who were diagnosed at the Sixth People's Hospital of Yancheng City during May 2013 till May 2015 were selected in this study, meanwhile another 112 healthy individuals were selected as the control subjects. The qPCR was performed to detect the serum miR-22 and miR-126 levels. Logistic regression analysis was conducted to analyze the independent factors influencing NSCLC metastasis, and receiver operating characteristic (ROC) curve was drawn to analyze the sensitivity and specificity of serum miR-22 and miR-126 levels in predicting NSCLC developments and metastasis. Results: The serum miR-22 level was significantly higher in the case group than that in the control group, while the serum miR-126 level was lower in the case group as compared with that in the control group (all P<0.05). Compared with squamous cell carcinoma patients, serum miR-22 level significantly increased (P<0.05), while serum miR-126 level decreased in patients with adenocarcinoma (P<0.01). Patients at III+IV stage showed increased serum miR-22 level and decreased serum miR-126 level as compared to patients at I + II stage (all P<0.01). In comparison to those without metastasis, patients with metastasis showed elevated serum miR-22 and decreased miR-126 level (all P<0.01). Compared with patients with familial inheritance,those without familial inheritance had increased serum miR-22 level but decreased serum miR-126 level (all P<0.01). The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC occurrence were 99.11% and 84.30%, 82.68% and 96.40%, respectively. The specificity and sensitivity of serum miR-22 and miR-126 levels in predicting NSCLC metastasis were 59.74% and 96.00%, 84.00% and 62.30%, respectively. Conclusion:miR-22 was high expressed while miR-126 was low expressed in the serum of NSCLC patients; they may be used as the predicative biomarkers for NSCLC development and metastasis.
Keywords:non-small cell lung cancer  miRNA-22  miRNA-126  blood serum  liquid biopsy
查看全文  查看/发表评论  下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved; ISSN: 1007-385X  CN 31-1725
主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会
地址:上海市杨浦区翔殷路800号 邮政编码:200433 京ICP备13026026号-2

本系统由北京勤云科技发展有限公司设计